Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026948.pdf
0001179110-16-026948.rtf
0001179110-16-026948.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026954.pdf
0001179110-16-026954.rtf
0001179110-16-026954.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026952.pdf
0001179110-16-026952.rtf
0001179110-16-026952.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026953.pdf
0001179110-16-026953.rtf
0001179110-16-026953.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026955.pdf
0001179110-16-026955.rtf
0001179110-16-026955.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026950.pdf
0001179110-16-026950.rtf
0001179110-16-026950.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026951.pdf
0001179110-16-026951.rtf
0001179110-16-026951.xls
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-006478.pdf
0001558370-16-006478.rtf
0001558370-16-006478.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-026165.pdf
0001179110-16-026165.rtf
0001179110-16-026165.xls
UPLOAD UPLOAD
0000000000-16-076961.pdf